RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara’s unique approach to influenza and how it differs from vaccines May 21, 2025
Cidara achieves full enrolment in influenza prevention trial December 5, 2024
How Cidara Got Its Molecule Back October 30, 2024
A Long-Lasting Drug Against Flu: Jeff Stein on The Long Run June 30, 2024
Cidara buys back rights to flu therapy from J&J for $85m April 25, 2024
Cidara buys back flu rights, sells antifungal and inks $240M PIPE April 24, 2024
Cidara regains rights to flu med after Janssen makes good on promise to divest April 2024
New Treatment Pathways for CD73-Expressing Tumors November 24, 2023
Cidara’s J&J-partnered immunotherapy could target flu and cancer October 26, 2023
PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares
Insights on the IND acceptance by the FDA to Treat Influenza June 6, 2022
4 Things to Know About the Flu in the Time of COVID-19 January 18, 2022
Johnson & Johnson Trying to Prevent Next Pandemic by Funding AVC Research* April 16, 2021
J&J Bets Up to $780 Million on Cidara’s Universal Influenza Treatment April 5, 2021
With one pandemic still raging, J&J bets $780M on a potential flu therapy for the next April 5, 2021
Janssen taps Cidara to develop new antiviral immunotherapies for flu April 5, 2021
Pioneering Antiviral Conjugates With Cidara’s Dr. Jeff Stein March 1, 2021
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease February 9, 2021
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings January 25, 2021
New and Emerging Drug Classes That Will Outlast the Pandemic December 31, 2020
Pharma’s Almanac Roundtable: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years? December 9, 2020
Pharma’s Almanac Roundtable: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic? December 9, 2020
Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19 October 14, 2020
Cidara Therapeutics Aims to Prevent Future COVID-19/Flu Season ‘Twindemics’ October 7, 2020
Long-Lasting Strategies for the Treatment and Prevention of COVID-19 September 2020
Companies To Watch: Cidara Therapeutics August 3, 2020
Applying the Principles of Immunotherapy to Infectious Diseases July 1, 2020
Cidara Platforms Targeting Prophylactics and Treatments for Fungal, Viral Infections June 16, 2020
Hallelujah! A Universal Flu Preventative and Therapy with Jeff Stein, Cidara May 21, 2020
5 Biopharma Execs Reveal Corporate Culture Best Practices May 1, 2020
Developing respiratory therapeutics for prophylaxis and treatment April 30, 2020
Contagion Connect Episode 7 – The ID Pipeline: Rezafungin & Antiviral Fc-Conjugates April 2, 2020
Catching Up to Coronavirus: Top 60 Treatments in Development March 19, 2020
Hallelujah! A Universal Flu Preventative and Therapy with Jeff Stein, Cidara September 12, 2019
The 2018 Flu Vaccine Was Only 29% Effective — but Experts Still Recommend It July 10, 2019
Cidara Advances Antiviral Conjugate to Treat and Prevent Flu May 17, 2019
How long do vaccines last? The surprising answers may help protect people longer April 18, 2019
Cidara Developing Investigational Flu Antiviral April 18, 2019
Cidara Cloudbreak and Antiviral Conjugates April 18, 2019
Cloudbreak Antiviral Conjugate Demonstrates Potent In Vitro Activity April 16, 2019
Evaluating Cloudbreak Molecule for Protection Against Acinetobacter Pneumonia April 15, 2019
A Novel Influenza Antiviral in Development Could Offer Months of Illness Prevention April 4, 2019
* During this interview, it was misstated that there were 80 million deaths in the U.S. due to influenza from 2017-2018. According to the CDC, 80,000 peopled died due to influenza from 2017-2018.
